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Abstract
Objectives: There is controversy over whether hepatocellular carcinoma (HCC) should be primarily
treated with living donor liver transplantation (LDLT) if liver resection (LR) can be effective. This retro-
spective study was conducted to compare survival outcomes in patients treated with either modality for
solitary HCC measuring ≤8 cm in diameter.
Methods: Outcomes in patients with solitary HCC primarily treated by LDLT were analysed. Patients with
solitary HCC of similar sizes with or without microvascular invasion primarily treated with LR were
selected at a ratio of 6 : 1 for comparison.
Results: In-hospital mortality amounted to 0% and 1.3% in the LDLT (n = 50) and LR (n = 300) groups,
respectively (P = 0.918). Complication rates were 34% and 20% in the LDLT and LR groups, respectively
(P = 0.027). Rates of 1-, 3-, 5- and 10-year overall survival were 98%, 94%, 89% and 83%, respectively,
in the LDLT group and 95%, 85%, 76% and 56%, respectively, in the LR group (P = 0.013). Rates of 1-,
3-, 5- and 10-year disease-free survival were 96%, 90%, 87% and 81%, respectively, in the LDLT group
and 81%, 64%, 57% and 40%, respectively, in the LR group (P < 0.0001).
Conclusions: Living donor liver transplantation surpassed LR in survival outcomes, achieving a 10-year
overall survival rate 1.5 times as high and a 10-year disease-free survival rate twice as high as those
facilitated by LR. However, it entailed more complications, in addition to the inevitable risks to the donor.
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Introduction
Liver resection (LR) and liver transplantation (LT) are accepted
surgical treatments for hepatocellular carcinomas (HCCs)
meeting standard criteria1,2 in patients with preserved liver func-
tion and decompensated liver function, respectively. Liver resec-
tion is readily available, but is associated with a high incidence of
recurrence and may compromise subsequent LT.3 Liver transplan-
tation is theoretically the best option because it cures both the
tumour and the underlying liver disease. However, it is limited by
the availability of liver grafts although theoretically living donor
liver donation is an alternative source of grafts for transplantation.
Patients with solitary HCC generally achieve good survival after
LR4,5 or LT.6 The present study was conducted to investigate the
outcomes of LR and living donor LT (LDLT), respectively, in these
patients.
Materials and methods
A retrospective analysis of data for all adult patients (aged ≥18
years) in whom solitary HCC was treated with LDLT as the
primary treatment during the period from 1996 to 2010 at the
University of Hong Kong was conducted. Tumour status was
based on histopathological examination of resected specimens. A
histopathological tumour diameter of 8 cm was used as the cut-off
criterion because no HCC of >8 cm had been encountered in
LDLTs performed at the study hospital. A group of adult patients
in whom HCCs of similar sizes with or without microvascular
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invasion were treated with primary LR during the same period
were selected on a ratio of 6 : 1 for comparison. This ratio was
adopted because the highest possible power for analysis was 1 : 6
according to the number of patients in the LR group with HCCs of
<5 cm in diameter and no microvascular invasion (Table 1). The
LR patients were selected randomly using a computer run by a
statistician. All data were collected prospectively by a single
research assistant.
The strategies for the management of patients with known
HCC and the selection of such patients for LDLT and LR have
been described elsewhere.7,8 For LDLT, in general this institution’s
practice has followed the University of California San Francisco
(UCSF) criteria, but patients with solitary HCC with a radiologi-
cal size of slightly over 6.5 cm have been accepted provided that
both the donor and recipient accepted the higher chance of recur-
rence. Tumours were evaluated using computed tomography (CT)
or magnetic resonance imaging (MRI) of the abdomen and
thorax, in addition to a radionuclide bone scan performed at
the initial diagnosis. Computed tomography was the first-line
imaging modality, whereas MRI was performed in patients with
a history of allergy or renal impairment or in whom the findings
of CT were inconclusive. In recent years, dual-tracer (18F-
fluorodeoxyglucose and 11C-acetate) positron emission tomogra-
phy has been performed in selected patients to exclude
extrahepatic metastasis. All living graft donors had a compatible
ABO blood group, serology negative of hepatitis B surface antigen
and hepatitis C antibody, and no evidence of any acute or chronic
illness that would increase operation risk.
All patients were submitted to regular follow-up at the outpa-
tient clinic by the surgical team and to regular surveillance for
recurrence by serial α-fetoprotein level checks and helical contrast
CT or MRI every 3 months in the first 2 years and every 6 months
thereafter. Intrahepatic tumour recurrences were managed with
re-resection, salvage transplantation, radiofrequency ablation or
transarterial chemoembolization according to tumour status and
liver function at the time of recurrence. Follow-up data for all
patients were complete.
Operative procedures were defined using the Brisbane termi-
nology. Major hepatectomy was defined as resection of four or
more liver segments. Resection of fewer than four liver segments
and non-anatomical resection were regarded as representing
minor hepatectomy. Postoperative complications were evaluated
according to the Clavien–Dindo system of classification. Hospital
death was defined as death after surgery during the same hospi-
talization. Survival was defined as the period from the time of
surgery to the time of death or time of data censoring. Recurrence
was calculated from the time of surgery to the time of diagnosis of
HCC recurrence and was censored at the time of the last follow-up
visit or death if at that time there was no evidence of recurrence.
The primary endpoint of the study was overall survival. The sec-
ondary endpoint was disease-free survival, which was defined as
the absence of recurrence of HCC and death (excluding hospital
deaths) after surgery. Deaths from all events were censored. Con-
tinuous variables were expressed as medians and ranges and com-
pared using the Mann–Whitney U-test. Categorical variables were
compared using Pearson’s chi-squared test. Survival analysis was
performed using the Kaplan–Meier method and compared
between groups with the log-rank test. All analyses were per-
formed using pasw Statistics for Windows Version 18.0 (SPSS,
Inc., Chicago, IL, USA). P-values of <0.05 were considered to
indicate statistical significance.
Results
A total of 720 adult patients with solitary HCC of ≤8 cm in diam-
eter underwent surgery at the study hospital during the study
period. Among them, 50 underwent LDLT and 432 underwent LR.
For the purposes of comparison, 300 patients were selected from
the 432 LR patients based on the matching of tumour size (<5 cm
and 5–8 cm) and the presence or absence of microvascular
Table 1 Distribution of patients grouped by tumour size and microvascular invasion before and after the matching of liver resection (LR)
patients to living donor liver transplantation (LDLT) patients at a ratio of 6 : 1
LR group, n LDLT group, n Total, n
Before matching
<5 cm without microvascular invasion 223 32 255
<5 cm with microvascular invasion 87 7 94
5–8 cm without microvascular invasion 75 7 82
5–8 cm with microvascular invasion 47 4 51
Total 432 50 482
After matching
<5 cm without microvascular invasion 192 32 224
<5 cm with microvascular invasion 42 7 51
5–8 cm without microvascular invasion 42 7 49
5–8 cm with microvascular invasion 24 4 28
Total 300 50 350
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invasion. Table 1 shows the distribution of patients grouped by
tumour size and the presence or absence of microvascular inva-
sion before and after matching.
Table 2 shows demographic and preoperative data for patients
in the LR and LDLT groups. Patients in the LDLT group had
significantly worse liver function. In the LR group, 112 (37%)
patients underwent major hepatectomy and 188 (63%) under-
went minor hepatectomy. The median resection margin was 1 cm
(range: 0–4.5 cm). In the LDLT group, all patients except one
received a right lobe graft. The median graft weight was 585 g
(range: 415–930 g), the median graft : standard liver volume ratio
was 47.1% (range: 31.7–79.2%), and the median graft : recipient
weight ratio was 0.88 (range: 0.58–1.41). Table 3 shows
intraoperative and postoperative data for patients in the two
groups.
Recurrence
Table 4 displays the patterns of primary and recurrent disease and
treatments for recurrence in the two groups. In the LR group, the
median time to recurrence was 18.9 months (range: 1–126.7
months). In the LDLT group, the median time to recurrence was
26 months (range: 10–57 months). All patients with recurrence in
this group, other than one who had extrahepatic recurrence, died
from progression of disease.
Survival
No hospital deaths occurred in the LDLT group, but four (1.3%)
deaths occurred in the LR group. One patient died of ischaemic
heart disease and three patients died of liver failure after the
operation. Rates of 1-, 3-, 5- and 10-year overall survival were
95%, 85%, 76% and 56%, respectively, in the LR group, and 98%,
94%, 89% and 83%, respectively, in the LDLT group (P = 0.013)
(Fig. 1). Rates of 1-, 3-, 5- and 10-year disease-free survival were
81%, 64%, 57% and 40%, respectively, in the LR group, and 96%,
90%, 87% and 81%, respectively, in the LDLT group (P < 0.0001)
(Fig. 2). Within the LDLT group, patients with HCCs of <5 cm
and patients with HCCs of 5–8 cm in diameter achieved compa-
Table 2 Demographic and preoperative data for the liver resection (LR) and living donor liver transplantation (LDLT) groups
LR group LDLT group P-value
(n = 300) (n = 50)
Age, years, median (range) 53 (19–65) 54 (30–64) 0.493
Gender, male : female, n 245 : 55 39 : 11 0.539
Hepatitis B virus infection, n (%) 276 (92%) 42 (84%) 0.121
Hepatitis C virus infection, n (%) 11 (4%) 5 (10%) 0.046
Comorbidity, n (%) 110 (37%) 18 (36%) 0.928
Child–Pugh class, n (%) <0.0001
A 291 (97%) 18 (36%)
B 9 (3%) 20 (40%)
C 0 12 (24%)
Total bilirubin, umol/l, median (range) 12.0 (2–58) 33.5 (8–570) <0.0001
INR, median (range) 1.0 (0.8–1.6) 1.3 (1.0–3.6) <0.0001
Albumin, g/l, median (range) 41 (23–50) 33 (21–43) <0.0001
Aspartate transaminase, U/l, median (range) 38 (13–393) 62.5 (29–349) <0.0001
Prothrombin time, s, median (range) 12.5 (9.5–18.2) 16.1 (10.8–38.7) <0.0001
Platelet count, ×109/l, median (range) 152.0 (27–421) 59.5 (25–215) <0.0001
Urea, mmol/l, median (range) 4.7 (2.3–13.6) 4.6 (2.5–23.8) 0.575
Creatinine, umol/l, median (range) 88 (35–839) 80 (38–210) 0.005
ICG retention at 15 min, %, median (range) 10.4 (1.2–78.0) 35.3 (8.0–56.1) <0.0001
MELD score, median (range) 7.72 (6–20) 13.00 (6–43) <0.0001
Tumour size, cm, median (range) 3.5 (0.7–8.0) 2.5 (1.0–7.5) 0.122
α-fetoprotein, ng/ml, median (range) 47.5 (2–32 843) 42.5 (2–12 020) 0.658
Microvascular invasion, n (%) 66 (22%) 11 (22%) >0.99
Tumour cell differentiation, n (%) 0.027
Good 96 (32%) 22 (44%)
Moderate 160 (53%) 23 (46%)
Poor 38 (13%) 0
Not known 2 (0.7%) 5 (10%)
INR, international normalized ratio; ICG, indocyanine green; MELD, Model for End-stage Liver Disease.
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rable survival (P = 0.720) (Fig. 3). In patients with HCCs of
≤2 cm, HCCs of >2 cm but <5 cm, and HCCs of 5–8 cm, recipi-
ents of LDLT tended to have better overall survival than recipients
of LR, but the difference did not reach statistical significance
(P = 0.090, 0.205 and 0.161, respectively) (Figs 4–6).
Discussion
In this study, both LDLT and LR performed to treat solitary HCC
of ≤8 cm resulted in good longterm survival. Living donor LT is a
Table 3 Intraoperative and postoperative data for patients in the liver resection (LR) and living donor liver transplantation (LDLT) groups
LR group LDLT group P-value
(n = 300) (n = 50)
Graft weight, g, median (range) – 585 (415–930) –
Blood loss, l, median (range) 0.60 (0.01–15.0) 2.02 (0.25–15.5) <0.0001
Blood transfusion, n (%) <0.0001
No 277 (93%) 19 (38%)
Yes 23 (7%) 31 (62%)
Hospital death, n (%) 4 (1%) 0 0.918
Hospital stay, days, median (range) 8 (2–102) 16 (7–38) <0.0001
Follow-up, months, median (range) 71.8 (0.2–210.8) 70.4 (5.9–178.5) 0.751
Postoperative complications, n (%) 60 (20%) 17 (34%) 0.027
Clavien–Dindo Grades I and II 20 (7%) 4 (8%)
Clavien–Dindo Grade IIIa 28 (9%) 12 (24%)
Clavien–Dindo Grade IIIb 3 (1%) 0
Clavien–Dindo Grade IV 5 (2%) 1 (2%)
Clavien–Dindo Grade V 4 (1%) 0
Table 4 Patterns of primary and recurrent disease and treatments for
recurrence in the liver resection (LR) and living donor liver transplan-
tation (LDLT) groups
LR group LDLT group P-value
(n = 146) (n = 5)
Primary HCC, n (%)
Within Milan criteria 123 (84%) 5 0.741
Beyond Milan criteria 23 (16%) 0
With microvascular invasion 42 (29%) 1 >0.99
Without microvascular
invasion
104 (71%) 4
First recurrence of HCC, n (%)
Intrahepatic 127 (87%) 2 0.022
Extrahepatic 19 (13%) 3
Within Milan criteria 68 (47%) 0 0.109
Beyond Milan criteria 78 (53%) 5
Treatment of intrahepatic
recurrence, n
(n = 127) (n = 2)
Re-resection 33 0
Salvage transplantation 4 0
Local ablative therapy 23 0
Transarterial
chemoembolization
55 2
Others 12 0
HCC, hepatocellular carcinoma.
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Figure 1 Overall survival in patients with solitary hepatocellular car-
cinomas of ≤8 cm in diameter submitted to liver resection (LR) or
living donor liver transplantation (LDLT)
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technically more demanding operation, as evidenced by the
higher complication rate, longer hospital stay and greater blood
loss. However, rates of 1-, 3-, 5- and 10-year overall survival were
98%, 94%, 89% and 83%, respectively, in the LDLT group, and
95%, 85%, 76% and 56%, respectively, in the LR group (P =
0.013). Rates of 1-, 3-, 5- and 10-year disease-free survival were
96%, 90%, 87% and 81%, respectively, in the LDLT group, and
81%, 64%, 57% and 40%, respectively, in the LR group (P <
0.0001). The superiority of LDLT in terms of survival (overall as
well as disease-free survival) became more conspicuous as time
progressed. The 10-year disease-free survival rate achieved by
LDLT was more than twice as good as that achieved by LR. The
trend can also be observed in the three subgroups of patients with
HCCs of ≤2 cm, HCCs of >2 cm but <5 cm, and HCCs of 5–8 cm,
respectively, but without statistical significance, probably because
the number of patients in each subgroup was small.
This study is one of the few items in the literature to demon-
strate the role of LDLT in the management of solitary HCC. Living
donor LT may be a plausible option, especially in young patients
suffering from solitary HCC of ≤8 cm in size. The limited avail-
ability of liver grafts demands a system that selects the best recipi-
ent for a transplant rather than one that selects the best treatment
for a patient. Decisions on voluntary liver donation represent a
complicated psychological process for a potential donor that
involves various social, cultural, interpersonal and family factors.
Decisions on LDLT are not based on a comparison of the out-
comes predicted for two patients, but on the balance between
donor risks and recipient benefits.
The debate on the choice of primary transplantation versus
primary resection is ongoing. A strategy of primary resection with
salvage transplantation for intrahepatic recurrence has been pro-
posed and may represent a reasonable approach for early HCC in
patients with preserved liver function. Initial resection of HCC as
a primary therapy allows for a good quality of life as patients do
not need longterm immunosuppression. Moreover, it is less
demanding than LT. Furthermore, grafts are saved for patients
who have no treatment option other than transplantation.3,9,10 By
contrast, LT is theoretically the best curative treatment for HCC.
Firstly, it removes the tumour with the widest possible margin
together with any intrahepatic metastasis. Secondly, it cures the
underlying cirrhosis that is responsible for both hepatic decom-
pensation and the development of a metachronous tumour after
partial hepatectomy.
Several studies have compared the outcomes of various thera-
pies performed for HCC with curative intent3,9–14 and have
observed LR and LT to have similar overall outcomes. Rahbari
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Figure 2 Disease-free survival in patients with solitary hepatocellular
carcinomas of ≤8 cm in diameter submitted to liver resection (LR) or
living donor liver transplantation (LDLT)
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Figure 3 Overall survival in patients with solitary hepatocellular car-
cinomas of <5 cm or 5–8 cm in diameter submitted to living donor
liver transplantation
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et al.15 reviewed nine such studies and found that most of them did
not identify any significant difference in patient survival. Nonethe-
less, when evaluated in an intention-to-treat analysis, the results of
LT were much less satisfactory.16,17 This probably reflected the
occurrence of dropouts from waiting lists as a result of tumour
progression and death. In fact, the yield of LT seems directly related
to the length of wait. Majno et al.,18 using a predictive decision
model, suggested that LR would have a better outcome than LT if
the wait exceeded 6 months, which is the case in most countries at
present. It is important to note that most of these studies included
cases of deceased donor LT (DDLT)9,11,12,18–21 or a combination of
DDLTs and LDLTs.10,13 Adult LDLT is a relatively novel procedure
with a short history and therefore its longterm outcome in the
treatment of HCC is not yet well established.
Comparisons of DDLT and LDLT have been made in the
context of treatment of HCC, and tendencies towards a higher
rate of recurrence and a lower rate of survival after LDLT have
been reported. A previous study conducted at the present centre
reported cumulative 5-year recurrence rates of 29% in LDLT
patients and 0% in DDLT patients who met the radiological Milan
or UCSF criteria.22 The multicentre Adult-to-Adult Living Donor
Liver Transplantation Cohort Study (A2ALL) reported similar
findings of recurrence within 3 years of transplantation.23 Roayaie
et al.24 reported a tendency for early recurrence after LDLT (mean
time to recurrence: 8.7 months) compared with DDLT (mean
time to recurrence: 19.6 months). Unlike in DDLT, patients
seldom drop out of LDLT wait lists and thus tumours in recipients
of LDLT might be more aggressive than those of DDLT recipients.
Moreover, small-for-size graft injury and liver regeneration may
enhance tumour growth and invasiveness.25,26
A study conducted in 2004 at the present centre reported a
mean waiting time for DDLT in Hong Kong of 344 days and a
dropout rate of 70%.8 A long waiting time and a high dropout rate
provide justification for LDLT, with which the uncertainty about
waiting time and the risk for dropping out can virtually be elimi-
nated, and the overall applicability of LT has risen from 12% to
>50%. In regions with a low rate of deceased donor organ dona-
tion and good LDLT results, there is a trend towards offering
LDLTs to patients with HCC but preserved liver function.27,28
Hepatocellular carcinoma accounts for a third of the indications
for LT in Asia, and 96% of LTs for HCC are LDLTs.29
Microscopic venous invasion has been shown to be the most
important adverse prognostic factor in both LR and LT for
HCC.30–34 Tumour size and tumour number are useful surrogate
markers of the biological behaviour of HCCs and represent pre-
dictors of survival.6,31,35 Thus, in the present study, tumour size
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Figure 4 Overall survival in patients with solitary hepatocellular car-
cinomas of ≤2 cm in diameter submitted to liver resection (LR) or
living donor liver transplantation (LDLT)
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Figure 5 Overall survival in patients with solitary hepatocellular car-
cinomas of >2 cm but <5 cm in diameter submitted to liver resection
(LR) or living donor liver transplantation (LDLT)
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and microvascular invasion were used as parameters to match
recipients of LR and LDLT in order to compare the outcomes of
the two treatment modalities.
In the literature, survival after LR in transplantable patients with
early HCC is comparable with that after LT, but the incidence of
recurrence after LR is higher as a result of intrahepatic metastasis
and metachronous hepatocarcinogenesis in cirrhotic liver
remnants.12,36–38 Similarly, the LR group in the present study dem-
onstrated comparable overall survival (76% versus 89%) but worse
disease-free survival (57% versus 87%) at 5 years. The worse 5-year
disease-free survival translates, at least partly, into the difference in
10-year survival between the two groups. This shows that longer-
term outcome is important in this type of comparative study.
Salvage LT is one of the measures for treating recurrent HCC
after LR. In an intention-to-treat analysis by Cherqui et al.,39 close
monitoring with imaging after LR allowed 61% of patients with
recurrence to undergo salvage LT. However, primary resection
denies the chance of LT to initially transplantable patients who
become unsuitable for salvage LT because their recurrent disease
exceeds the criteria for transplantation. In the present study, 31%
of cases of first recurrence in the LR group were beyond the Milan
criteria. In addition to the failure to fulfil particular criteria, there
are other reasons that prevent the performance of LT for recur-
rence, such as advanced age, acquired comorbidity and patient
refusal.40 Salvage LDLT for HCC that recurs after curative treat-
ment is associated with a high risk for re-recurrence even if the
recurrent HCC is within standard criteria, and salvage LDLT itself
has been identified as an independent poor prognostic factor that
affects recurrence-free survival after LDLT for HCC.41
As LR can achieve a 10-year disease-free survival rate of 40%, as
seen in the present study, LDLT may be considered as representing
an over-treatment when donor risk is considered. It may arguably
be unethical to subject a healthy person to risk when there is an
alternative option of resection with acceptable longterm survival.
It is also important to note that outcomes in patients who have
recurrence of HCC after LT are worse than those in patients who
have recurrence after LR, as demonstrated in a previous study
conducted at this centre.5
Limitations and controversies
This research is derived from a single-centre study with a relatively
small number of LDLT recipients, and did not take account of
some transplant-related complications that can compromise
longterm survival, such as graft rejection, opportunistic infection,
and other malignancies resulting from immunosuppression.
Furthermore, it does not represent an intention-to-treat analy-
sis, and the determination of tumour number and status was not
based on preoperative radiological imaging, but on histopatho-
logical examination of the excised livers and resected specimens.
Hence there are two possible sources of limitation. Firstly, it is
possible that the study excluded patients who were believed to
have solitary HCC before transplantation but were found to have
multiple tumours in their excised livers. The study’s inclusion
of only patients with solitary HCC partly explains the excellent
outcomes in both groups of patients. The adoption of
histopathological criteria rather than radiological criteria avoided
any heterogeneity in disease stage in both groups in the analysis.
Secondly, it is possible that HCCs may have been undetected in
the remnant livers of LR recipients. If this were so, then the LR
group in fact consisted of patients with different numbers of
tumours, meaning that the two groups of patients were incompa-
rable in terms of disease stage. Nonetheless, the ‘unfair’ effect of
this possible incomparability was minimal given that only six
(2%) of the 300 LR recipients were found to have intrahepatic
HCC on postoperative imaging within 3 months of resection
[four patients (1.3%) with solitary tumours and two patients
(0.7%) with multifocal tumours] and, among these, four patients
(1.3%) failed to survive a whole decade after resection. The
remaining two patients underwent subsequent resection of their
solitary tumours and survived for >10 years after the first resec-
tion. It is apparent that the survival outcome in the LR group has
hardly been unfavourably affected.
Conclusions
This study shares with the surgical community an experience
gained over 15 years at the only liver transplant centre in Hong
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Figure 6 Overall survival in patients with solitary hepatocellular car-
cinomas of 5–8 cm in diameter submitted to liver resection (LR) or
living donor liver transplantation (LDLT)
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Kong, which demonstrates that both LR and LDLT achieved good
longterm survival in patients with solitary HCC of ≤8 cm, but that
LDLT surpassed LR by demonstrating a 10-year overall survival
rate 1.5 times as high and a 10-year disease-free survival rate twice
as high. The study was not intended to promote LT in patients
who are beyond the Milan or UCSF criteria, as only 11 patients in
the LDLT group had HCCs of ≥5 cm. Neither does the study
intend to discourage LR and encourage LDLT in treating the
disease because the fact that LDLT is associated with a higher rate
of complications and, most importantly, with risk to a healthy
person’s health and life cannot be discounted. Good practice
should ensure that any decisions on treatment for HCC are made
on a case-by-case basis.
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